Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acquired fructose intolerance is a condition in which the body can not properly absorb the sugar, fructose. As a result, affected people may experience gastrointestinal symptoms, such as gas, abdominal pain, bloating and/or diarrhea, depending on the quantity of fructose consumed and the presence of other sugars ingested with it. Gastrointestinal symptoms related to acquired fructose intolerance appear to be more common in people who have an underlying functional bowel disorder such as irritable bowel syndrome. The underlying cause of the condition is poorly understood. It is distinct from the rare, genetic form of fructose intolerance (called hereditary fructose intolerance), which usually develops earlier in life and often affects more than one family member. Acquired fructose intolerance is generally managed with dietary modifications.
Biomarker and diagnostic research for acquired fructose intolerance has been reported in the published literature.
No clinical trials have been registered for acquired fructose intolerance.
23 publications have been identified in PubMed for acquired fructose intolerance. Research spans Epidemiology / Natural History (35%), Diagnostic / Biomarker (17%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 8 | 35% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
Common questions about acquired fructose intolerance
Testing and diagnosis research
4 |
17% |
Clinical study results | 4 | 17% |
Other research | 2 | 9% |
Research summaries | 2 | 9% |
Laboratory research | 2 | 9% |
Patient case studies | 1 | 4% |
Faria DPB (2026). [PMID: 42207072](https://pubmed.ncbi.nlm.nih.gov/42207072/). *Arq Gastroenterol*. [Epidemiology / Natural History]
Mikhael-Moussa H (2026). [PMID: 40197400](https://pubmed.ncbi.nlm.nih.gov/40197400/). *Am J Gastroenterol*. [Epidemiology / Natural History]
Andreyev HJN (2026). [PMID: 41922986](https://pubmed.ncbi.nlm.nih.gov/41922986/). *BMC Prim Care*. [Clinical Trial Publication]
Heras JL (2026). [PMID: 41806524](https://pubmed.ncbi.nlm.nih.gov/41806524/). *Clin Nutr*. [Clinical Trial Publication]
Agarwal M (2026). [PMID: 41884203](https://pubmed.ncbi.nlm.nih.gov/41884203/). *World J Gastrointest Pathophysiol*. [Clinical Trial Publication]
Kriegshäuser G (2026). [PMID: 41952413](https://pubmed.ncbi.nlm.nih.gov/41952413/). *J Neurogastroenterol Motil*. [Other]
Coursan A (2026). [PMID: 41418890](https://pubmed.ncbi.nlm.nih.gov/41418890/). *Brain Behav Immun*. [Basic Science / Preclinical]
Schnedl WJ (2026). [PMID: 41241218](https://pubmed.ncbi.nlm.nih.gov/41241218/). *Clin Nutr ESPEN*. [Diagnostic / Biomarker]
Zhang K (2026). [PMID: 42211734](https://pubmed.ncbi.nlm.nih.gov/42211734/). *Aquac Nutr*. [Other]
DeChristopher LR (2025). [PMID: 40135583](https://pubmed.ncbi.nlm.nih.gov/40135583/). *Public Health Nutr*. [Epidemiology / Natural History]